Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Farmers Insurance
McKesson
Medtronic
Cerilliant
AstraZeneca
Chubb
Teva
Harvard Business School
Mallinckrodt

Generated: February 21, 2018

DrugPatentWatch Database Preview

AMELUZ Drug Profile

« Back to Dashboard

When do Ameluz patents expire, and what generic alternatives are available?

Ameluz is a drug marketed by Biofrontera and is included in one NDA. There is one patent protecting this drug.

This drug has thirteen patent family members in eleven countries.

The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.
Summary for AMELUZ
Drug patent expirations by year for AMELUZ
Pharmacology for AMELUZ
Ingredient-typePorphyrinogens
Drug ClassPorphyrin Precursor
Medical Subject Heading (MeSH) Categories for AMELUZ

US Patents and Regulatory Information for AMELUZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biofrontera AMELUZ aminolevulinic acid hydrochloride GEL;TOPICAL 208081-001 May 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Biofrontera AMELUZ aminolevulinic acid hydrochloride GEL;TOPICAL 208081-001 May 10, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for AMELUZ

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Julphar
US Department of Justice
Cantor Fitzgerald
Daiichi Sankyo
QuintilesIMS
AstraZeneca
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot